WST Shareholders Have the Right to Lead the West Pharmaceutical Services, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - WST
Werte in diesem Artikel
LOS ANGELES, July 7, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against West Pharmaceutical Services, Inc. ("West" or "the Company") (NYSE: WST) for violations of the federal securities laws.
Shareholders who purchased the Company's securities between February 16, 2023 and February 12, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before July 7, 2025.
CASE DETAILS: The complaint alleges that the Company made false and misleading statements to the market concerning whether West claimed to have strong visibility into customer demand, but suffered from significant destocking of its High-Value Products portfolio. The Company's SmartDose device, purportedly a high-margin product, was in fact dilutive of its profit margins due to inefficiencies. The Company suffered margin pressures increasing the risk of restructuring such as exiting continuous glucose monitoring contacts with long-term customers.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/wst-shareholders-have-the-right-to-lead-the-west-pharmaceutical-services-inc-securities-lawsuit---contact-the-djs-law-group-to-discuss-your-rights---wst-302498517.html
SOURCE DJS Law Group LLP
Übrigens: West Pharmaceutical Services und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf West Pharmaceutical Services
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf West Pharmaceutical Services
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu West Pharmaceutical Services Inc.
Analysen zu West Pharmaceutical Services Inc.
Datum | Rating | Analyst | |
---|---|---|---|
06.11.2012 | West Pharmaceutical Services hold | Jefferies & Company Inc. | |
14.05.2010 | West Pharmaceutical Services neutral | UBS AG | |
06.11.2007 | West Pharmaceutical Services buy | UBS AG | |
08.10.2007 | West Pharmaceutical Services neues Kursziel | UBS AG | |
20.08.2007 | West Pharmaceutical Services Ersteinschätzung | UBS AG |
Datum | Rating | Analyst | |
---|---|---|---|
06.11.2007 | West Pharmaceutical Services buy | UBS AG |
Datum | Rating | Analyst | |
---|---|---|---|
06.11.2012 | West Pharmaceutical Services hold | Jefferies & Company Inc. | |
14.05.2010 | West Pharmaceutical Services neutral | UBS AG | |
08.10.2007 | West Pharmaceutical Services neues Kursziel | UBS AG | |
20.08.2007 | West Pharmaceutical Services Ersteinschätzung | UBS AG |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für West Pharmaceutical Services Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen